TG Therapeutics, Inc.
TGTXTG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of hematologic cancers and autoimmune diseases. The company’s portfolio includes agents aimed at addressing unmet medical needs in multiple sclerosis, B-cell malignancies, and other related conditions. Based in the United States, TG Therapeutics is engaged in both research and development efforts to bring innovative treatments to patients.
Company News
Kuehn Law is investigating whether officers and directors of TG Therapeutics breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term TGTX stockholders to participate in shareholder litigation, offering free consultations with no obligation.
TG Therapeutics announced a collaboration with actress Christina Applegate, who has lived with MS for 5 years, to raise awareness and support meaningful conversations for people living with multiple sclerosis. The partnership launched a new platform called www.NextInMS.com during Super Bowl LX, featuring Christina's personal perspectives and expe...
U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trad...
TG Therapeutics' CEO Michael S. Weiss will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, discussing the company's developments in B-cell disease treatments.
TG Therapeutics reported strong Q2 2025 results with BRIUMVI sales growth, raising full-year revenue guidance to $585 million. The company is focusing on expanding product reach, developing new dosing regimens, and exploring additional indications for its multiple sclerosis therapy.
